探索BRCA突变型与HR野生型高级别浆液性卵巢癌的差异:一项多组学分析
本研究利用CARIS数据库对2745例高级别浆液性卵巢癌(HGSOC)肿瘤样本进行下一代测序和全转录组测序,比较BRCA1突变、BRCA2突变与同源重组野生型(HRwt)肿瘤的转录组特征。结果发现BRCA2突变型肿瘤的TMB-H最高,而BRCA1突变型肿瘤中NKT细胞浸润、T细胞炎症评分、IFNγ评分及PDL1表达更高。结论强调基于BRCA1和BRCA2突变的不同免疫特征,并提示潜在治疗靶点。
要点
- BRCA1突变、BRCA2突变和HRwt/LOH高、HRwt/LOH低分别占19%、11%、27%和43%。
- BRCA2突变型肿瘤的TMB-H最高,高于BRCA1突变、HRwt/LOH高和HRwt/LOH低肿瘤。
- BRCA1突变型肿瘤中NKT细胞浸润、T细胞炎症评分、IFNγ评分及PDL1表达更高。
核心结论
- 研究结果强调基于BRCA1和BRCA2突变的不同免疫特征,并提示包括免疫治疗和靶向特定基因组改变在内的潜在治疗靶点。
研究设计与样本
- 利用CARIS数据库对2745例HGSOC肿瘤样本进行下一代测序和全转录组测序(WTS;Caris Life Sciences,Phoenix,AZ)。
- BRCA突变定义为导致蛋白功能丧失的变异,HRwt定义为BRCA1和BRCA2以及另外28个HR基因均无异常的样本。
- HRwt组进一步分为HRwt/LOH低(<16%)和HRwt/LOH高(≥16%)。
- 基因组分析包括突变分析以及TMB和MSI检测;转录组分析包括差异表达基因(DEGs)识别、GSEA和免疫去卷积。
主要发现
- 共识别519例(19%)BRCA1突变、302例(11%)BRCA2突变、739例(27%)HRwt/LOH高和1181例(43%)HRwt/LOH低HGSOC。
- TP53是所有组中最常见的突变基因。
- PIK3CA突变在HRwt/LOH低组中最常见,高于BRCA1突变和BRCA2突变HGSOC。
- TMB-H在BRCA2突变组中最高,高于BRCA1突变、HRwt/LOH高和HRwt/LOH低肿瘤。
- BRCA1突变肿瘤中观察到更高的NKT细胞浸润、更高的T细胞炎症评分和IFNγ评分以及更高的PDL1表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to evaluate the transcriptomic profile of BRCA1 mutant (BRCA1mut) and BRCA2 mutant (BRCA2mut) HGSOC compared to homologous recombination wild-type (HRwt) tumors utilizing the CARIS database. METHODS: Next-generation and Whole Transcriptome Sequencing (WTS; Caris Life Sciences, Phoenix, AZ) was performed on a total of 2745 HGSOC tumor samples. BRCA mutations were defined as variants resulting in loss-of-function of the protein and HRwt was defined as samples wildtype for aberrations in both BRCA1 and BRCA2, as well as for 28 other HR genes. HRwt group was further classified into HRwt/LOH-low (<16 %) and HRwt/LOH-high (≥16 %). Genomic analysis consists of mutation analysis and measurements of TMB and MSI. Transcriptomic analysis included identification of Differentially expressed genes (DEGs), GSEA and immune deconvolution. RESULTS: We identified 519 (19 %) BRCA1-mut, 302 (11 %) BRCA2-mut, and 739 (27 %) HRwt/LOH high and 1181 (43 %) HRwt/LOH low HGSOC. TP53 was the most commonly mutated gene in all groups. Mutations in PIK3CA were most common in HRwt/LOH-low compared to BRCA1-mut and BRCA2-mut HGSOC. TMB-H was highest in BRCA2-mut compared to BRCA1-mut, HRwt/LOH high and HRwt/LOH low tumors. In contrast, higher NKT cell infiltration, higher T cell inflamed and IFNγ scores, and higher PDL1 expression were observed in BRCA1-mut tumors. CONCLUSION: Our findings emphasize the differential immune profiles based on BRCA1 and BRCA2 mutations and suggest potential therapeutic targets, including treatment strategies that incorporate immunotherapy and target specific genomic alterations.
引用
- Alvero AB, Wu S, Farrell A, et al. Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis. Gynecol Oncol. 2025. PMID: 39970633. doi:10.1016/j.ygyno.2025.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。